Mayelin Gonzalez Alonso
Family · Hialeah, FLNPI 1750745733
Payments from drug & device makers
Across 100 payments — averaging $25.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$497
- AstraZeneca$303
- AbbVie$251
- UCB, Inc.$235
- Otsuka America Pharmaceutical, Inc.$222
- Novartis$214
- plus $823 from 16 others
What the payments were for
- Food & beverage$2,544100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 17 | $497 |
| AstraZeneca | 9 | $303 |
| AbbVie | 13 | $251 |
| UCB, Inc. | 8 | $235 |
| Otsuka America Pharmaceutical, Inc. | 12 | $222 |
| Novartis | 7 | $214 |
| Pfizer | 5 | $125 |
| Lilly USA, LLC | 5 | $105 |
| Johnson & Johnson | 3 | $83 |
| Teva Pharmaceuticals USA, Inc. | 2 | $63 |
| Lundbeck LLC | 2 | $62 |
| Dexcom, Inc. | 2 | $51 |
| EMD Serono, Inc. | 2 | $50 |
| Sumitomo Pharma America, Inc. | 2 | $50 |
| Amneal Pharmaceuticals LLC | 2 | $40 |
| Philips North America LLC | 2 | $39 |
| Genentech USA, Inc. | 2 | $38 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Aucta Pharmaceuticals, Inc. | 1 | $27 |
| Abbott | 1 | $27 |
| Acadia Pharmaceuticals Inc | 1 | $19 |
| Biogen | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ULTOMIRIS$120
How this compares
$2,544 in reported general payments places this provider in the 85th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 17 | $8,488 |
| Memantine Hcl | 203 | $2,259 |
| Rivastigmine | 15 | $1,687 |
| Donepezil Hcl | 205 | $1,094 |
| Gabapentin | 92 | $769 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 22 | $351 |
| Duloxetine Hcl | 25 | $268 |
| Sertraline Hcl | 32 | $160 |
| Levetiracetam | 13 | $159 |
| Topiramate | 20 | $127 |
| Trazodone Hcl | 41 | $108 |
| Primidone | 18 | $79 |
| Escitalopram Oxalate | 14 | $69 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCRytary | $40 | $8,48817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 14,618 family providers in Florida.
Other family in Hialeah
- David RodriguezHialeah$658K
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.